With every passing day, new discoveries are made that lend support to the increasing and important role biomarker analysis and tumor profiling play in personalized cancer care. Caris Life Sciences® is actively participating in research to advance the understanding of molecular science, further enabling the delivery of precision medicine.

View Posters & Abstracts for:
Caris Molecular Intelligence®  | ADAPT Biotargeting System™

View Caris Manuscripts on PubMed:

2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010

  • Characterization of neuroendocrine breast carcinomas for biomarkers of therapeutic options

    ESR1 mutations, ESR1 fusions and co-occurring alterations assessed in breast cancer tumors

    Programmed death 1 (PD-1) and PD-1 ligand (PD-L1) distribution in triple negative breast cancer TNBC

    Use of an aptamer library based next generation omics platform for the development of a novel trastuzumab

    Racial differences in the molecular landscape of breast

    Read More

  • Medulloblastoma candidate pathways for novel treatment strategies

    Novel targets in ependymal tumors

    PD-1,PD-L1 and genomic expression profiling of meningiomas

    Pemetrexed A potential new therapeutic option for the treatment of Thymidylate Synthase

    Results of molecular profiling for recurrent malignant gliomas

    Read More

  • Comparative molecular analyses of BRAF-V600E mutant tumors: Colorectal cancers (CRC) vs. melanomas

    Comparative molecular analyses of colon versus rectal tumors

    Ras family mutation patterns in a large cohort of CRCs

    Comparative molecular analyses of esophageal cancer: Adenocarcinoma vs. squamous cell carcinomas and impact on outcome

    Comparative molecular analyses of pancreatic cancer (PC): KRAS wild type vs. KRAS mutant tumors and primary tumors vs. distant metastases

    Comparison of molecular alteration in glioblastoma tumors from old and young patients

    Differences in the molecular landscape of cancer between African American (AA) and Caucasian (CC) cancer patients

    Use of panomic assessment to reveal DNA repair alterations and to predict potential therapeutic response to taxane-platinum combination therapy in prostate cancer

    Disparity in PD-L1 expression between metastatic uveal and cutaneous melanoma

    Predictive value of toposisomerase 1 immunohistochemistry (TOP1 IHC) in patients with metastatic breast cancer receiving irinotecan-based therapy

    Distribution of PD-L1 expression in diverse cancer types: Experience with over 10,000 cases

    Tumor profiling of liver metastases (LM) from CRC, NSCLC, pancreatic (PC), breast (BC) and gastroesophageal (GE) tumors to reveal differences versus primary tumors including in cMET, MYC, CDK4, Her2, b-catenin and PD1

    Novel panomic validation of time to next treatment (TNT) as an effective surrogate outcome measure in 4,729 patients

    Fusion analysis of solid tumors to reveal novel rearrangements in breast carcinomas

    Read More

  • Caris will deliver 10 poster presentations at the 2016 American Association for Cancer Research (AACR) Annual Meeting from April 16-20, in New Orleans, La., including one late-breaking poster presentation. See what others said about AACR this year on Twitter.

    Adaptive dynamic artificial poly-ligand targeting (ADAPT) enables plasma-based exosome profiling with potential diagnostic utility (Late-Breaker)

    Multiplatform molecular profiling of invasive lobular breast cancer

    Analysis of MET-amplified solid tumors using chromogenic in situ hybridization (CISH)

    Molecular and genomic characterization of SCLC

    Clinico-pathological and molecular features associated with TP53 mutation in 3457 molecularly-profiled colorectal cancers (CRCs)

    Frequent BRCA2 somatic mutations in colorectal cancer patients with mircrosatellite instability (MSI)

    Mutations on the homologous recombination pathway in 13 cancer types

    Caveolin-1: Beyond a marker for basal-like breast cancers

    Expression of class III beta-tubulin (TUBB3) in 3580 colorectal cancers (CRCs) and correlation with clinico-pathological and molecular features

    A rationale for treatment of colorectal cancer with mitomycin C and crizotinib

    Read More

  • Uterine leiomyosarcomas exhibit distinct drug resistance molecular profiles compared to extrauterine leiomyosarcomas-A comprehensive analysis of 1023 leiomyosarcomas

    Vulvar and vaginal melanoma-A distinct subclass of melanoma based on a comprehensive molecular analysis of 51 cases

    Identification of Molecular Targets in Vulvar Cancers

    Unique Molecular Signatures Between High-Grade and Low-Grade Endometrial Stromal Sarcoma-An Analysis of 96 Cases

    Profiling of Triple Negative Endometrial Cancers (TNEC) and Triple Negative Breast Cancers (TNBC) Reveals Unique Expression Profiles

    Molecular Profiling Reveals Distinct Molecular Landscapes in 545 Cases of Triple Negative Endometrial Cancer

    Multiplatform tumor-profiling of 50 malignant Sertoli-Leydig cell tumors of the ovary reveals therapeutic

    Read More